Business context and reporting period
The supplied filing is ITUS Corporation’s unaudited Form 10-Q for the quarter and nine months ended July 31, 2016—not an Anixa Biosciences filing. ITUS was shifting its focus from patent licensing to Cchek, a cancer-diagnostics platform developed with The Wistar Institute; it reported no Cchek revenue. The company said it expanded its Wistar arrangement on August 15, 2016. Legacy patent licensing continued on a limited basis.
Financial performance and position
| Metric | Three months ended July 31, 2016 | Nine months ended July 31, 2016 |
|---|---|---|
| Revenue | $100,000 | $100,000 |
| Operating costs and expenses | $1.075 million | $3.696 million |
| Operating loss | $975,000 | $3.596 million |
| Net loss | $1.104 million | $3.969 million |
| Net loss per share, basic and diluted | $0.13 | $0.45 |
| Cash used in operating activities | Not provided for the quarter | $2.699 million |
At July 31, 2016, cash and cash equivalents were $2.049 million and short-term certificates of deposit were $1.900 million, totaling $3.949 million in cash and short-term investments. Current assets were $4.006 million, current liabilities $532,000, and working capital approximately $3.474 million. Total assets were $6.321 million; total liabilities $4.603 million; shareholders’ equity $1.718 million. The $4.071 million patent acquisition obligation is the principal reported debt-like obligation; it is due no later than November 2017, subject to royalties, and the November 2017 payment may be made in cash or common stock at the company’s option. Interest expense of $383,000 for nine months reflects accretion on this obligation. No gross margin is reported.
Material changes versus comparable periods
- Nine-month revenue fell to $100,000 from $9.255 million, primarily because the prior-year period included $9 million from the AU Optronics settlement. Patent-licensing revenue was $100,000 versus $255,000.
- Nine-month net loss was $3.969 million versus $87,000 in the prior-year period, which included the AUO settlement. The prior-year settlement and related costs make this comparison unusually affected by nonrecurring items.
- For the quarter, revenue increased to $100,000 from $95,000 and net loss narrowed to $1.104 million from $1.602 million. Lower general and administrative costs, especially stock-based compensation, contributed to the improvement.
- Nine-month operating cash flow shifted to a $2.699 million use from $2.165 million provided in the prior-year period. Cash, cash equivalents, and short-term investments declined by about $2.820 million from October 31, 2015.
- Marketing, general and administrative expense declined to $3.306 million from $5.152 million for nine months; stock-option compensation included in that expense was $570,000 versus $2.338 million.
Outlook, risks and unusual items
Management said, based on information available August 19, 2016, that existing cash, short-term investments, and expected cash flows should fund activities for at least 12 months. It cautioned that actual cash needs may differ, and that additional equity or debt financing might be unavailable or unfavorable; equity or convertible debt could dilute shareholders. If funding is insufficient and expenses cannot be reduced, the company may need to curtail or cease some operations. Management said it did not expect Cchek to generate revenue in the immediate future.
Management cited favorable initial Cchek testing in a small breast-cancer sample and announced successful lung-cancer detection in April 2016; a more extensive clinical study was underway. These are company-reported early-stage results, not evidence in this filing of validated commercial performance. The filing reported no material change in previously disclosed risk factors, no material pending litigation beyond ordinary-course matters and patent enforcement, and effective disclosure controls. It also reported no material adverse effect expected from ordinary-course legal matters.
Important facts for investors to verify
- Confirm the issuer identity: this filing names ITUS Corporation, despite the request metadata naming Anixa Biosciences Inc.
- Review the Wistar agreement, study design, sample sizes, results, and development costs; the filing provides limited detail on the ongoing study.
- Assess cash burn against the stated 12-month runway and the possibility of future financing, dilution, or operating cuts.
- Review the terms, timing, and settlement method for the $4.071 million patent acquisition obligation, including the November 2017 cash-or-stock option.
- Distinguish recurring operating performance from the prior-year $9 million AUO settlement and related nonrecurring expenses.
- Consider potential dilution: 8,747,753 common shares were outstanding on August 15, 2016, and the filing lists substantial outstanding options and convertible preferred stock.